KRAS and neoplasm: QTX3034 (Quanta Therapeutics), RSC-1255 (RasCal Therapeutics), and YL-17231 (TEB-17231, Shanghai YingLi Pharmaceutical Co., Shanghai, China) are other pan-RAS inhibitors that have also demonstrated durable inhibition of KRAS signaling in vivo and tumor growth in vitro [45,46,47].